{"id":"desmopressin-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyponatremia (water intoxication)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Facial flushing"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Desmopressin mimics the action of endogenous antidiuretic hormone (ADH/vasopressin) by selectively activating V2 receptors in the renal collecting ducts, promoting aquaporin-2 water channel insertion and increasing water reabsorption. This reduces urine volume and increases urine osmolality. It has minimal vasopressor activity compared to native vasopressin due to its selectivity for V2 over V1 receptors.","oneSentence":"Desmopressin is a synthetic vasopressin analog that binds to V2 receptors on kidney collecting duct cells to increase water reabsorption and reduce urine output.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:20.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Central diabetes insipidus"},{"name":"Nocturnal enuresis (bedwetting)"},{"name":"Polycystic kidney disease (adjunctive)"},{"name":"Von Willebrand disease and mild hemophilia A"}]},"trialDetails":[{"nctId":"NCT06771128","phase":"NA","title":"Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2024-11-01","conditions":"Nocturnal Enuresis in Children, Desmopressin, Monosymptomatic Nocturnal Enuresis","enrollment":398},{"nctId":"NCT07028645","phase":"","title":"Uroflowmetry and Nocturnal Enuresis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Furkan Adem Canbaz","startDate":"2022-08-20","conditions":"Enuresis, Nocturnal","enrollment":100},{"nctId":"NCT06772584","phase":"NA","title":"Ginko Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2024-01-01","conditions":"Enuresis, Nocturnal","enrollment":90},{"nctId":"NCT04329975","phase":"","title":"Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2020-05-19","conditions":"Nocturia Due to Nocturnal Polyuria","enrollment":1087},{"nctId":"NCT04420585","phase":"PHASE4","title":"Desmopressin for Bedwetting in Children With SCD","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2020-07-07","conditions":"Nocturnal Enuresis, Anemia, Sickle Cell","enrollment":8},{"nctId":"NCT06185361","phase":"NA","title":"Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis.","status":"UNKNOWN","sponsor":"Fayoum University Hospital","startDate":"2022-12-01","conditions":"Nocturnal Enuresis, Enuresis, Enuresis, Nocturnal","enrollment":60},{"nctId":"NCT05617664","phase":"NA","title":"Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-11-23","conditions":"Nocturnal Enuresis","enrollment":150},{"nctId":"NCT02636387","phase":"","title":"Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2015-08-26","conditions":"Nocturnal Enuresis, Anemia, Sickle Cell","enrollment":14},{"nctId":"NCT03201419","phase":"PHASE2","title":"A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2017-07-27","conditions":"Nocturia","enrollment":302},{"nctId":"NCT04586790","phase":"PHASE2","title":"the Effect of Oral Vasopressors for Liberation From IV Vasopressors in Spinal Shock","status":"UNKNOWN","sponsor":"Ahmed talaat ahmed aly","startDate":"2020-10-15","conditions":"Spinal Shock","enrollment":90},{"nctId":"NCT02905682","phase":"PHASE3","title":"Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-09","conditions":"Nocturia","enrollment":190},{"nctId":"NCT02904759","phase":"PHASE3","title":"Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-09","conditions":"Nocturia","enrollment":342},{"nctId":"NCT01036841","phase":"PHASE4","title":"Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2009-12","conditions":"Enuresis, Polyuria","enrollment":24},{"nctId":"NCT03051009","phase":"PHASE3","title":"Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2017-01-11","conditions":"Nocturia","enrollment":503},{"nctId":"NCT01729819","phase":"PHASE2","title":"Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2013-01","conditions":"Overactive Bladder","enrollment":106},{"nctId":"NCT01552343","phase":"PHASE3","title":"Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2012-03","conditions":"Nocturia","enrollment":56},{"nctId":"NCT02729766","phase":"PHASE2, PHASE3","title":"Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-03","conditions":"Inappropriate ADH Syndrome","enrollment":15},{"nctId":"NCT02084797","phase":"NA","title":"V2 Receptor Effects on Fluid Regulation and Performance","status":"COMPLETED","sponsor":"Oakland University","startDate":"2011-06","conditions":"Electrolyte Imbalance, Hyponatremia, Hypernatremia","enrollment":10},{"nctId":"NCT00615836","phase":"PHASE3","title":"An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (\"Melt\") Formulation of Desmopressin for the Treatment of Nocturia in Adults","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-12","conditions":"Nocturia","enrollment":554},{"nctId":"NCT01262456","phase":"PHASE3","title":"Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2011-02","conditions":"Nocturia","enrollment":395},{"nctId":"NCT01223937","phase":"PHASE3","title":"Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2010-11","conditions":"Nocturia","enrollment":268},{"nctId":"NCT01779466","phase":"PHASE2","title":"Daytime Impact Sleep Study","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2013-04","conditions":"Nocturia","enrollment":5},{"nctId":"NCT01576900","phase":"","title":"The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2012-04","conditions":"Nocturia","enrollment":124},{"nctId":"NCT01684800","phase":"PHASE2","title":"Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2012-09","conditions":"Nocturia","enrollment":178},{"nctId":"NCT01694498","phase":"PHASE2","title":"Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2012-09","conditions":"Nocturia","enrollment":183},{"nctId":"NCT01368913","phase":"","title":"MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2011-06","conditions":"Nocturnal Enuresis","enrollment":138},{"nctId":"NCT01280188","phase":"PHASE3","title":"A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2011-01","conditions":"Central Diabetes Insipidus","enrollment":20},{"nctId":"NCT01184859","phase":"PHASE2","title":"Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2010-07","conditions":"Nocturia","enrollment":116},{"nctId":"NCT01078753","phase":"PHASE3","title":"Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2010-01","conditions":"Nocturnal Enuresis","enrollment":89},{"nctId":"NCT00209261","phase":"PHASE4","title":"A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2004-12","conditions":"Primary Nocturnal Enuresis","enrollment":221},{"nctId":"NCT00230594","phase":"PHASE3","title":"Desmopressin Response in the Young","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2004-07","conditions":"Primary Nocturnal Enuresis","enrollment":132},{"nctId":"NCT00902265","phase":"","title":"Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2009-02","conditions":"Nocturia Associated With Nocturnal Polyuria","enrollment":138},{"nctId":"NCT00835211","phase":"PHASE1","title":"Desmopressin Acetate 0.2 mg Tablets, Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-07","conditions":"Healthy","enrollment":48}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"C-REACTIVE PROTEIN INCREASED"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"DECREASED APPETITE"},{"count":1,"reaction":"DYSARTHRIA"},{"count":1,"reaction":"FALL"},{"count":1,"reaction":"HYPONATRAEMIA"},{"count":1,"reaction":"OLIGURIA"},{"count":1,"reaction":"PLEURAL EFFUSION"},{"count":1,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DDAVP"],"phase":"marketed","status":"active","brandName":"desmopressin tablet","genericName":"desmopressin tablet","companyName":"University Hospital, Ghent","companyId":"university-hospital-ghent","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Desmopressin is a synthetic vasopressin analog that binds to V2 receptors on kidney collecting duct cells to increase water reabsorption and reduce urine output. Used for Central diabetes insipidus, Nocturnal enuresis (bedwetting), Polycystic kidney disease (adjunctive).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}